<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03587545</url>
  </required_header>
  <id_info>
    <org_study_id>B300201835709</org_study_id>
    <nct_id>NCT03587545</nct_id>
  </id_info>
  <brief_title>Study of Probiotic Potential of Lactobacillus Strains in the Upper Respiratory Tract After Nasal Spray Application</brief_title>
  <official_title>Study of Probiotic Potential of Nasopharyngeal Lactobacillus Strains in the Upper Respiratory Tract After Nasal Spray Application</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Probiotics are defined as &quot;live micro-organisms that, when administered in adequate amounts,
      confer a health benefit to the host&quot; (Hill et al, 2014). These microbes are generally applied
      in the gastrointestinal tract via fermented food products or capsules. In previous research,
      the investigators isolated bacterial strains with potential probiotic properties for the
      upper respiratory tract based on in vitro laboratory tests, in vivo mice experiments and
      genome sequencing.

      In this study, the investigators want to deliver the Proof-of-Concept that the most promising
      isolated strain, Lactobacillus casei AMBR2 (LAMBR2) and the well-documented probiotic strain
      Lactobacillus rhamnosus GG (LGG) also have interesting properties in humans, i.e. that these
      strains are able to -temporarily- persist in the upper respiratory tract of healthy
      volunteers and CRS patients after daily nasal application via a nasal spray for 2 weeks. In
      addition, the investigators aim to explore whether the application of these strains has an
      impact on the nasopharyngeal microbiome via 16S rRNA amplicon sequencing and dedicated qPCR
      analysis.

      Therefore, bacterial DNA from nasal swabs will be isolated via commercially available DNA
      extraction kits, followed by Illumina MiSeq sequencing in order to identify the bacterial
      species present in these samples. Furthermore, the concentration of the Lactobacillus and
      specific pathogens will be monitored via qPCR.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Actual">October 10, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nasal persistence of lactobacilli</measure>
    <time_frame>3 years</time_frame>
    <description>After DNA extraction of the biological samples, the relative and absolute concentration of the administered probiotics will be monitored via microbiome analysis and qPCR. This will give information about the capacity of the probiotics to colonize the nasopharynx.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiome differences</measure>
    <time_frame>3 years</time_frame>
    <description>After Illumina MiSeq sequencing, bio-informatic tools will be used to cluster bacteria into amplicon sequence variants (ASVs). Based on these ASVs, the investigators will compare the composition of the bacteria in the sampled niches and compare this composition between patient with and without intake of probiotics. The investigators will specifically screen for ASVs that are over- or underrepresented in both populations. Furthermore, special attention will go to screen for the typical nasopharyngeal pathogens such as Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis... and also to beneficial microbes such as lactic acid bacteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic potential: chronic rhinosinusitis</measure>
    <time_frame>3 years</time_frame>
    <description>Chronic rhinosinusitis symptoms will be evaluated before and after administration of the nasal spray. Participants should rate the complaints linked to CRS from 'not present' to 'serious'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic potential: nasal hyperreactivity</measure>
    <time_frame>3 years</time_frame>
    <description>Nasal hyperreactivity symptoms will be evaluated before and after administration of the nasal spray.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic potential: SNOT-22 score</measure>
    <time_frame>3 years</time_frame>
    <description>The investigators will investigate whether the nasal intake of probiotics has an effect on the quality of life of CRS patients. Patients should rate general nasopharyngeal complaints from 0 to 5 where 0 means that there is no complaint and 5 means that there are serious complaints.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Chronic Rhinosinusitis (Diagnosis)</condition>
  <condition>Probiotics</condition>
  <condition>Sprays</condition>
  <condition>Nasal Disease</condition>
  <arm_group>
    <arm_group_label>Healthy probiotic group LGG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily intake by healthy volunteers of 2 dosages of LGG spray during 2 weeks. Probiotic nasal spray.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy probiotic group LAMBR2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily intake by healthy volunteers of 2 dosages of LAMBR2 spray during 2 weeks. Probiotic nasal spray.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily intake by healthy volunteers of 2 dosages of placebo spray during 2 weeks.
Placebo nasal spray.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRS probiotic group LGG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily intake by CRS patients of 2 dosages of LGG spray during 2 weeks. Probiotic nasal spray.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRS probiotic group LAMBR2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily intake by CRS patients of 2 dosages of LAMBR2 spray during 2 weeks. Probiotic nasal spray.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRS placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily intake by CRS patients of 2 dosages of placebo spray during 2 weeks. Placebo nasal spray.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Probiotic nasal spray</intervention_name>
    <description>Total daily nasal administration of 2*10^8 CFU of probiotic bacteria delivered via 2 servings.</description>
    <arm_group_label>CRS probiotic group LAMBR2</arm_group_label>
    <arm_group_label>CRS probiotic group LGG</arm_group_label>
    <arm_group_label>Healthy probiotic group LAMBR2</arm_group_label>
    <arm_group_label>Healthy probiotic group LGG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo nasal spray</intervention_name>
    <description>Two servings of nasal administration of placebo nasal spray (not containing probiotic bacteria)</description>
    <arm_group_label>CRS placebo group</arm_group_label>
    <arm_group_label>Healthy placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CRS patient group: CRS diagnosed

        Exclusion Criteria:

          -  no patients with trisomy 21

          -  no pregnant women

          -  no breastfeeding women

          -  no acute or chronic airway infections (except for CRS patients in CRS patient group)

          -  no cancer

          -  no autoimmune diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Lebeer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universiteit Antwerpen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Antwerp University Hospital</name>
      <address>
        <city>Edegem</city>
        <state>Antwerp</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://procureproject.be/en/</url>
    <description>Related Info</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 27, 2018</study_first_submitted>
  <study_first_submitted_qc>July 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2018</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Antwerp</investigator_affiliation>
    <investigator_full_name>Ethisch Comité, UZA</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nose Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

